Blood Res.  2015 Sep;50(3):126-128. 10.5045/br.2015.50.3.126.

Cellular immunotherapy as a beacon of hope for hematological malignancies

• Lee HJ
• Kim SK
• Cho D
• Lee JJ

• KMID: 2172752
• DOI: http://doi.org/10.5045/br.2015.50.3.126

Abstract

No abstract available.

MeSH Terms

Hematologic Neoplasms*
Hope*
Immunotherapy*

Reference

1. Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015; 15:201–215. PMID: 25786696.

2. Hoang MD, Jung SH, Lee HJ, et al. Dendritic cell-based cancer immunotherapy against multiple myeloma: from bench to clinic. Chonnam Med J. 2015; 51:1–7. PMID: 25914874.

3. Nguyen-Pham TN, Lee YK, Lee HJ, et al. Cellular immunotherapy using dendritic cells against multiple myeloma. Korean J Hematol. 2012; 47:17–27. PMID: 22479274.

4. Lee JJ, Kook H, Park MS, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher. 2004; 19:66–70. PMID: 15274198.

5. Nguyen-Pham TN, Jung SH, Vo MC, et al. Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma. J Immunother. 2015; 38:330–339. PMID: 26325377.

6. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015; 33:540–549. PMID: 25154820.

7. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014; 123:2625–2635. PMID: 24578504.

8. Cho D, Kim SK, Carson WE 3rd. NK cell-based immunotherapy for treating cancer: will it be promising? Korean J Hematol. 2011; 46:3–5. PMID: 21461294.

9. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010; 28:955–959. PMID: 20085940.

10. Chouaib S, Pittari G, Nanbakhsh A, et al. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol. 2014; 5:95. PMID: 24672522.